- Conditions
- Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Orange, California • Stanford, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 788
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
- Interventions
- PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
- Biological · Drug
- Lead sponsor
- Katy Peters, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
- Interventions
- Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
- Biological
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Interventions
- Dabrafenib, Trametinib, Hydroxychloroquine
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- RECURRENT GLIOBLASTOMA, Brain Tumor
- Interventions
- Optune(NOVOTTF-100A)
- Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Drug
- Lead sponsor
- Sanjiv Sam Gambhir
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Brain Tumor
- Interventions
- Tesevatinib
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
- Conditions
- Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
- Interventions
- Cyclophosphamide, Fludarabine, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- cediranib maleate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
- Interventions
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
- Drug · Radiation
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Up to 25 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab and Etoposide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
- Interventions
- PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2051
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Durham, North Carolina • Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- O6-benzylguanine, carmustine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- laromustine
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 10
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- O6-benzylguanine, temozolomide, filgrastim, pharmacological study, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 35 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 7 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- ATN-161, carboplatin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- chemotherapy, suramin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
- Interventions
- Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
- Drug · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
- Interventions
- G207
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 36 Months to 22 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Houston, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, R115777
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atypical Teratoid Rhabdoid Tumor, Central Nervous System Rhabdoid Tumor
- Interventions
- 21.15.GPC3-CAR T Cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2044
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma (Skin), Metastatic Cancer
- Interventions
- temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Beech Grove, Indiana + 24 more